Topamax for neuropathic pain
Johnson & Johnson will not seek a Topamax (topiramate) indication in diabetic neuropathic pain following Phase III data that failed to demonstrate a statistically significant effect on primary endpoints. Topamax is also in Phase III trials for prevention of migraine headache, treatment of bipolar mania, obesity and partial onset seizures
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth